Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

NCT07014254 | Not Yet Recruiting

• 1 other identifier: KY20252131-C-1
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This was a single-centre, single-arm, non-blinded, prospective study using 20 patients with advanced metastatic GI malignancies recruited to treat patients with advanced metastatic GI malignancies with 177Lu-CTR-FAPI to assess the safety of 177Lu-CTR-FAPI in advanced metastatic GI malignancies; this included radiation therapy dosimetry and initial treatment Determination of Effectiveness

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC); Adenocarcinoma of the Stomach; Colorectal Cancer Metastatic; Neuroendocrine Tumor (NET)

Keywords

177Lu-CTR-FAPI

Outcome Measures

Primary Outcomes (2)

• ORR

  Objective mitigation rate

  End of treatment (12 weeks)

• DCR

  Disease control rate

  End of treatment (12 weeks)

Study Arms (1)

177Lu-CTR-FAPI nuclide-targeted therapy

EXPERIMENTAL

177Lu-CTR-FAPI nuclide-targeted therapy in patients with advanced tumours lacking effective treatments

Drug: 177Lu-CTR-FAPI nuclide-targeted therapy

Interventions

177Lu-CTR-FAPI nuclide-targeted therapy DRUG

Fasting, special diets, or other specific preparations are not required on the day of 177Lu-CTR-FAPI administration. Patients were given 4 mg ondansetron 30 minutes before treatment to prevent nausea and vomiting. The radiopharmaceutical 177Lu-CTR-FAPI (200 ± 10% mCi) was diluted with 100 mL of 0.9% saline and given slowly by intravenous infusion over 20-30 minutes (flow rate 200 ml/h). Symptoms and vital signs were monitored before and after treatment. The treatment regimen was planned for a maximum of 3 courses of treatment, with 4-8 weeks between each cycle

177Lu-CTR-FAPI nuclide-targeted therapy

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. voluntary participation in this study and signing of informed consent;
• \. age 18-75 years (both 18 and 75 years);
• \. ECOG (Eastern Cooperative Oncology Group) physical status score: 0-1;
• Advanced metastatic gastrointestinal malignancies with high FAP expression: e.g. neuroendocrine tumours (NET G2, G3), neuroendocrine carcinomas (NEC), pancreatic ductal adenocarcinomas (PDAC), gastric adenocarcinomas, colorectal carcinomas, intrahepatic cholangiocarcinomas (ICC), and squamous carcinomas of the oesophagus. All of the above should be confirmed by 68Ga-FAPI PET/CT with high FAP expression (criterion: more than 50% of lesions with SUVmax ≥10). 5.
• \. Disease status: locally advanced unresectable or metastatic lesions confirmed by imaging (CT/MRI/PET-CT); at least 1 measurable lesion (RECIST 1.1 criteria).
• \. good major organ function, i.e. the following criteria are met (no blood components, cell growth factors are allowed within 14 days prior to the first dose)
• Creatinine clearance ≥ 50 ml/min (calculated according to the Cockcroft-Gault formula) or serum creatinine ≤ 150 μmol/L;
• Urine protein \<2+; if urine protein ≥2+, then 24-hour urine protein quantification must show \<2 g of protein;
• White blood cell count ≥ 2 × 109/L;
• Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;
• Platelets ≥ 75 × 109/L;
• Haemoglobin ≥ 8.0 g/dL;
• Serum albumin ≥ 30 g/L.
• Total bilirubin ≤ 3 × ULN;
• \. Women of childbearing age who undergo a blood pregnancy test within 72 h prior to treatment need to be excluded from pregnancy and must be non-lactating and willing to use a highly effective method of contraception for the duration of the trial and for 6 months after completion of treatment. For men, agreement to use a highly effective method of contraception or to have been surgically sterilised during the study and for 4 months after the end of treatment.

You may not qualify if:

• \. Disease-related:
• Combination of other malignancies (except non-melanoma skin cancer or radical tumours without recurrence within 5 years);
• Presence of central nervous system metastases or carcinomatous meningitis;
• Uncontrolled cancer pain (requiring long-term high-dose opioids) or cachexia (≥20% weight loss in 6 months);
• Diabetes mellitus (fasting blood glucose \> 2 x ULN) that is not well controlled with optimal medical supportive therapy;
• Accompanied by poorly controlled plasmapheresis, including pleural fluid, ascites, and pericardial effusion; controlled with treatment and stable (asymptomatic, not requiring interventional therapy, and stable on imaging) for ≥2 weeks may be included;
• Severe urinary incontinence, hydronephrosis, severe voiding dysfunction or the need for an indwelling urinary catheter for any reason;
• Subjects with uncontrolled cardiac clinical symptoms or disease, including but not limited to: i) NYHA class 2 or higher heart failure; ii) unstable angina; iii) myocardial infarction within 1 year prior to enrolment; iv) left ventricular ejection fraction (LVEF) \<50%; v) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;
• Co-occurring active hepatitis B (HBV-DNA testing is required for HBsAg-positive individuals with HBV DNA ≥500 IU/mL or 2500 copies/mL), and hepatitis C (HCV-Ab-positive and above the lower limit of detection of the analytical method);
• Persons known to have acquired immunodeficiency syndrome (AIDS) or human immunodeficiency virus (HIV) testing positive. Persons with active syphilis infection.
• \. Treatment related
• Radiotherapy within 4 weeks or previous radiotherapy to \>25% of the bone marrow area;
• Received systemic anti-tumour therapy such as chemotherapy, immunotherapy, targeted therapy within 4 weeks;
• Treatment with surgery (biopsy puncture, non-anti-tumour surgical operations such as ERCP may be excluded), radiofrequency ablation or cryoablation, interferon, transcatheter arterial embolisation (TAE) or transcatheter arterial chemoembolisation (TACE) within 12 weeks;
• Prior FAP-targeted therapy (e.g., FAPI-PRRT, anti-FAP antibody drugs);

Sponsors & Collaborators

• Xijing Hospital: lead

Study Sites (1)

Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an, Shaanxi Province Recruiting

Xi'an, Shaanxi, China

Location

MeSH Terms

Conditions

Neuroendocrine Tumors

Condition Hierarchy (Ancestors)

Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue

Central Study Contacts

Ying Guo Ying Guo

CONTACT

+862984771048; guoying01192022@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2025
• First Posted: June 10, 2025
• Study Start: June 20, 2025
• Primary Completion (Estimated): April 30, 2028
• Study Completion (Estimated): April 30, 2028
• Last Updated: June 10, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)